Department of Basic Medical Sciences, Faculty of Health Sciences, School of Medicine, Institute of Biomedical Technologies (ITB), University of La Laguna, 38071 Tenerife, Spain
Dr. Carmen Laura Sayas
Department of Basic Medical Sciences, Faculty of Health Sciences, School of Medicine, Institute of Biomedical Technologies (ITB), University of La Laguna, 38071 Tenerife, Spain
Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine kinase with a plethora of substrates. As a modulator of several cellular processes, GSK-3 has a central position in cell metabolism and signaling, with important roles both in physiological and pathological conditions. GSK-3 has been associated with a number of human disorders, such as neurodegenerative diseases including Alzheimer’s disease (AD). GSK-3 contributes to the hyperphosphorylation of tau protein, the main component of neurofibrillary tangles (NFTs), one of the hallmarks of AD. GSK-3 is further involved in the regulation of different neuronal processes that are dysregulated during AD pathogenesis, such as the generation of amyloid-β (Aβ) peptide or Aβ-induced cell death, axonal transport, cholinergic function, and adult neurogenesis or synaptic function. In this review, we will summarize recent data about GSK-3 involvement in these processes contributing to AD pathology, mostly focusing on the crucial interplay between GSK-3 and tau protein. We further discuss the current development of potential AD therapies targeting GSK-3 or GSK-3-phosphorylated tau.
31 January 2020 in Frontiers in Cellular Neuroscience